Cook Medical Technologies LLC

J.w. Medical Systems Ltd.

Cook Incorporated

Med Institute Incorporated

The Spectranetics Corporation

Other

Patrick H Ruane

David W Snow

Priscilla Reyes

William F Moore

Cameron Wilson

Melinda S Morrell

Darin Gene Schaeffer

Anthony O Ragheb

Andrew P Isch

Jeff P Little

Waleska Perez-Segarra

Blayne A Roeder

Neal E Fearnot

Thomas A Osborne

Brian L Bates

William D Voorhees, Iii

David Douglas Grewe

Randy Joe Myers

David Paul Biggs

Qi Zhan

Steven Ummel

Christine Casterline

Ashley P Lindsay

Arlene Alcantara

Jackie Joe Hancock

Amy M Vibbert

Zhan Qi

Cameron L Wilson

Priscilla T Reyes

Jeffery P Little

Christine L Casterline

A drug or agent coated balloon having a length which is adjustable in vivo is described herein. The balloon is configured to be coated or coatable with one or more drugs where the coating may be applied prior to advancement into a patient body or prior to balloon expansion within the patient body. The length of the expandable portion of the balloon is adjustable to approximate a length of the tissue region to be treated. Moreover, the drug-coated balloon may be used alone or it may be utilized to deploy luminal prostheses having one or more linked or otherwise coupled segments.

Adjustable-length drug delivery balloon

A method and device for local delivery of a water-insoluble therapeutic agent to the tissue of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with a non-durable coating which includes an amphiphilic polymer or copolymer, in embodiments polyethylene glycol, having a substantially water-insoluble therapeutic agent dispersed therein. In some embodiments, the coating may also include iodine. The medical disposable device is inserted into a body lumen, and expanded to contact the non-durable coating against the body lumen and deliver the substantially water-insoluble therapeutic agent to the body lumen tissue.

Coatings for medical devices

A method of forming a coated medical device is described in which a coating including a therapeutic agent dispersed in a polymer or oligomer matrix is applied to an outer surface of the medical device. The coating is then post-processed to selectively remove a substantial portion of the polymer or oligomer matrix from the coating. The post-processed coating is then sterilized.

Post-processing of a medical device to control morphology and mechanical properties

Medical devices for implantation within a body vessel comprising a graft material and a releasable therapeutic agent are provided. The graft material preferably comprises a biocompatible polyurethane and a therapeutic agent. Preferably, the medical device is a stent graft formed by attaching a polyurethane graft material comprising an elutable taxane therapeutic agent to a radially expandable frame.

Stent graft with releasable therapeutic agent and soluble coating

An implant comprises a structure that may be implanted into tissue and that has a first material property at normal body temperature. The first material property is variable at elevated temperatures above normal body temperature. The implant also has a plurality of particles dispersed in the structure that are adapted to convert incident radiation into heat energy when irradiated with electromagnetic radiation. The particles are in thermal contact with the structure such that exposure of the particles to incident radiation raises the temperature of the structure thereby changing the first material property relative to the first material property at normal body temperature.

Thermo-mechanically controlled implants and methods of use

The disclosure relates to medical devices coated with zein admixed with levulinic acid. The medical device may further include a therapeutic agent in contact with zein admixed with levulinic acid. Zein admixed with levulinic acid allows the therapeutic agent to be retained on the device during delivery and also controls the elution rate of the therapeutic agent following implantation. The disclosure further relates to methods of delivering a therapeutic agent on said medical devices as well as their use especially in the form of stents for prevention of restenosis.

Controlled drug delivery using a zein layer modified with levulinic acid

Methods of delivering a bioactive material to a body vessel are disclosed. The method steps can include providing an expandable medical device with a coating having a bioactive layer, and providing a second layer of a biodegradable polymer positioned over the bioactive layer. The second layer provides for controlled release of the bioactive material from the bioactive layer. The medical device is inserted into a body vessel using a catheter such that the medical device contacts the body vessel.

Method of delivering an implantable medical device with a bioabsorbable coating

This disclosure relates to implantable medical devices coated with a taxane therapeutic agent, such as paclitaxel, in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous and/or solvated solid forms of taxane therapeutic agents that provide durable coatings that release the taxane over a desired period of time, which can be varied in the absence of a polymer by selecting the type and amount of solid forms of the taxane therapeutic agent in the coating. Other preferred embodiments relate to methods of coating medical devices and methods of treatment. The coatings can provide a sustained release of the taxane therapeutic agent within a body vessel without containing a polymer to achieve the desired rate of paclitaxel elution.

Taxane coatings for implantable medical devices

The present invention provides an implantable medical device comprising a bioactive agent and poly(alkyl cyanoacrylate) polymer. In one embodiment of the invention, the bioactive agent is a water-soluble material, such as an antisense agent.

Implantable medical device coated with a bioactive agent

Methods of coating a medical device are provided to improve coating uniformity and reduce coating irregularities while reducing direct coating of the luminal surface of the medical device. Preferably, methods of coating a tubular medical device include the steps of: positioning the tubular medical device around a mandrel coating assembly, mounting the tubular medical device on the mandrel coating assembly and spraying a coating solution including a therapeutic agent and a solvent onto the abluminal surface of the tubular medical device mounted on the mandrel coating assembly. The mandrel coating assembly may include an axial member of a diameter that is less than the diameter of the lumen of the tubular medical device and at least one annular projection extending from the axial member to an outer surface having a diameter greater than or substantially equal to the diameter of the lumen of the medical device. Improved coating uniformity may be achieved by providing an annular space between the luminal surface of the medical device and an axial member. Coating on the luminal surface may be minimized by providing an axial member having an outer diameter that is greater than the maximum width or length of the spray contacting the axial member after passing through the openings in the medical device.

Mandrel and method for coating open-cell implantable endovascular structures

Growing community of inventors

Redwood City, CA, United States of America

Patrick H Ruane